Bell & Brown Wealth Advisors LLC Sells 1,070 Shares of Eli Lilly and Company $LLY

Bell & Brown Wealth Advisors LLC trimmed its stake in Eli Lilly and Company (NYSE:LLY) by 7.8% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 12,577 shares of the company’s stock after selling 1,070 shares during the period. Eli Lilly and Company comprises about 3.5% of Bell & Brown Wealth Advisors LLC’s investment portfolio, making the stock its 7th biggest position. Bell & Brown Wealth Advisors LLC’s holdings in Eli Lilly and Company were worth $9,811,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also recently added to or reduced their stakes in the company. Precedent Wealth Partners LLC lifted its holdings in Eli Lilly and Company by 15.3% during the 2nd quarter. Precedent Wealth Partners LLC now owns 294 shares of the company’s stock valued at $229,000 after purchasing an additional 39 shares during the last quarter. Capital Advisors Inc. OK grew its holdings in Eli Lilly and Company by 6.8% during the second quarter. Capital Advisors Inc. OK now owns 6,747 shares of the company’s stock valued at $5,260,000 after purchasing an additional 429 shares during the period. Family CFO Inc acquired a new position in shares of Eli Lilly and Company in the second quarter valued at approximately $54,000. Duquesne Family Office LLC boosted its holdings in shares of Eli Lilly and Company by 52.5% in the first quarter. Duquesne Family Office LLC now owns 94,830 shares of the company’s stock valued at $78,321,000 after buying an additional 32,640 shares during the period. Finally, Corient IA LLC acquired a new position in Eli Lilly and Company during the first quarter worth $570,000. 82.53% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several analysts have issued reports on the stock. Leerink Partners reaffirmed a “market perform” rating and set a $715.00 price target on shares of Eli Lilly and Company in a research report on Thursday, August 7th. UBS Group dropped their price objective on shares of Eli Lilly and Company from $1,050.00 to $895.00 and set a “buy” rating on the stock in a research report on Friday, August 8th. JPMorgan Chase & Co. dropped their price objective on shares of Eli Lilly and Company from $1,100.00 to $1,050.00 and set an “overweight” rating on the stock in a research report on Tuesday, September 16th. Weiss Ratings reissued a “hold (c+)” rating on shares of Eli Lilly and Company in a research report on Wednesday, October 8th. Finally, Daiwa America lowered shares of Eli Lilly and Company from a “strong-buy” rating to a “hold” rating in a research report on Sunday, August 17th. One investment analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and nine have issued a Hold rating to the company. According to MarketBeat.com, Eli Lilly and Company presently has an average rating of “Moderate Buy” and a consensus target price of $939.12.

Eli Lilly and Company Trading Down 1.9%

LLY stock opened at $803.53 on Friday. The company has a debt-to-equity ratio of 1.86, a quick ratio of 1.00 and a current ratio of 1.28. The company’s 50-day simple moving average is $753.09 and its 200 day simple moving average is $766.23. Eli Lilly and Company has a 52 week low of $623.78 and a 52 week high of $935.63. The company has a market capitalization of $760.51 billion, a PE ratio of 52.52, a price-to-earnings-growth ratio of 1.17 and a beta of 0.47.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings results on Thursday, August 7th. The company reported $6.31 EPS for the quarter, beating the consensus estimate of $5.59 by $0.72. The business had revenue of $15.56 billion for the quarter, compared to the consensus estimate of $14.40 billion. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. Eli Lilly and Company’s revenue was up 37.6% compared to the same quarter last year. During the same period in the prior year, the company posted $3.92 earnings per share. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. As a group, sell-side analysts anticipate that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Insider Activity

In other news, Director Gabrielle Sulzberger acquired 117 shares of Eli Lilly and Company stock in a transaction on Tuesday, August 12th. The shares were purchased at an average cost of $641.18 per share, for a total transaction of $75,018.06. Following the completion of the purchase, the director directly owned 2,703 shares of the company’s stock, valued at approximately $1,733,109.54. This represents a 4.52% increase in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO David A. Ricks acquired 1,632 shares of Eli Lilly and Company stock in a transaction on Tuesday, August 12th. The shares were purchased at an average price of $644.77 per share, for a total transaction of $1,052,264.64. Following the completion of the purchase, the chief executive officer directly owned 546,601 shares of the company’s stock, valued at approximately $352,431,926.77. This represents a 0.30% increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last three months, insiders acquired 4,514 shares of company stock valued at $2,894,841. Company insiders own 0.13% of the company’s stock.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.